Eric Benevich joins Neurocrine Biosciences as Chief Commercial Officer

He was most recently Vice President of Marketing at Avanir Pharmaceuticals

Neurocrine Biosciences, a US developer of pharmaceuticals for neurological and endocrine-based diseases, says Eric Benevich has joined the company as Chief Commercial Officer.

Benevich was most recently at Avanir Pharmaceuticals as Vice President of Marketing, where he was responsible for Nuedextra and commercialisation of their CNS pipeline. He has more than 20 years of experience in the pharmaceutical industry with Peninsula Pharmaceuticals, Amgen and AstraZeneca.

You may also like

Regulatory

Tardive dyskinesia – valbenazine

There are currently no approved treatments for tardive dyskinesia, and the symptoms are frequently irreversible
Research & Development

Drug licensing deals in 2010

Big pharma companies have been busy filling the yawning gaps in their product pipelines by licensing drugs developed by smaller biotechnology firms. Dr Sarah Houlton outlines a selection of the deals done this year
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Hybrid interferons: developing a novel drug class

With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Manufacturing

Anton Paar expands Litesizer DIA Series with new models

Introducing affordable and advanced solutions for particle analysis
Manufacturing

Triple your efficiency with the new DrySyn Vortex

Boost productivity with temperature-controlled parallel reactions
Subscribe now